insights_auto
Why is BNTX down 3.35%?
Dive Deeperchevron_right
BNTX:NASDAQ
BioNTech SE - ADR
$92.06
arrow_downward
-3.35%(-3.19) 1D
$92.50
arrow_upward
+0.48% (+0.44)bedtimeAfter hours
Closed: Oct 8, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BNTX...
Open
$93.81
High
$94.45
Low
$91.64
Mkt. cap
23.13B
Avg. vol.
995.12K
Volume
1.21M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.55
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
Open
$93.81
High
$94.45
Low
$91.64
Mkt. cap
23.13B
Avg. vol.
995.12K
Volume
1.21M
52-wk high
$123.98
52-wk low
$79.52
EPS
-$7.55
Beta
1.22
Shares outstanding
251.20M
No. of employees
8K
News stories
From web sources and news partners
The Motley Fool
·
6 hours ago
BioNTech Has More Cancer Drugs in Late-Stage Trials Than Most Investors Realize. Is It a Buy Under $100?
Yahoo Finance
·
9 hours ago
BioNTech SE (BNTX) Stock Forecasts
AD HOC NEWS
·
13 hours ago
Morgan Stanley cuts target for BioNTech stock to USD 114.00
Simply Wall Street
·
19 hours ago
Is BioNTech (BNTX) Undervalued On Pipeline Promise Despite Revenue Of €2,650.0 Million And Losses?
Profile
BioNTech SE is a German multinational biotechnology company headquartered in Mainz that develops immunotherapies and vaccines, particularly for cancer and infectious diseases.
The company utilizes technology platforms including mRNA-based therapies, targeted therapies, and immunomodulators, to develop its treatments. BioNTech's pipeline includes several late-stage programs in oncology testing combination therapy approaches to improve treatment outcomes.
In the field of infectious diseases, BioNTech, partnering with Pfizer, developed Comirnaty, the first approved mRNA-based vaccine, which was widely used during the COVID-19 pandemic. Wikipedia
About BioNTech SE - ADR